- Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment
approaches have failed; biopsy is not required for recurrent disease.
- Cohort 2: Newly-diagnosed high-grade glioma (World Health Organization [WHO] grade 3
- Life expectancy ≥ 3 months
- Diagnosis of brainstem glioma
- Concurrent administration of any other anti-tumor therapy
- Pre-existing uncontrolled diarrhea